论文信息 - Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias - 字舞流文

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

M. Konopleva | M. Andreeff | H. Kantarjian | G. Garcia-Manero | J. Cortes | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | S. Kornblau | Z. Zeng | J. Burger | N. Pemmaraju | W. Wierda | B. Ragon | H. Schneider | Lakiesha Debose | Brittany Knick Ragon | Courtney D DiNardo